The American Hospital Association (AHA) asked the Biden administration this week to immediately withdraw the Trump administration’s “most favored nation” (MFN) drug pricing interim final rule, in part, because of the damage it will do to 340B hospitals and “critical services and programs their patients rely on.”
“Substantial” Medicare Part B drug reimbursement cuts for 340B hospitals under the rule “will force hospitals to make difficult decisions about whether to reduce or even eliminate some services, as resources may need to be re-directed to ensure that patients can continue to receive drugs subject to the MFN rule,” AHA said in Jan. 25 comments to U.S. Centers for Medicare & Medicaid Services (CMS) Acting Administrator Liz Richter. “In addition, the revenue lost by hospitals will affect their ability to expand clinical services and invest in necessary infrastructure.”
The American Hospital Association (AHA) asked the Biden administration this week to immediately withdraw the Trump administration’s “most favored nation” (MFN) drug pricing interim final rule, in part, because of the damage it will do to 340B hospitals and “critical services and programs their patients rely on.”
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.